In low- and middle- income countries, the price of medicine is the single most important factor determining availability and affordability. In high-income countries, where medicine reimbursement systems are often in place, the prices for innovative medicines too are impacting on government buying. This workshop will cover international drug pricing issues through country-level case studies from around the globe. This included countries with stable and supportive medicine reimbursement systems such as Australia, New Zealand, and Canada as well as countries that are much more market-driven such as the USA and Malaysia. The examples would also include from Pakistan, India, and Bangladesh. The range of medicine pricing mechanisms includes policies based on cost-plus pricing, value-based pricing, pricing, and innovation in the pharmaceutical industry and the countries where pharmacoeconomic analysis is compulsory for drug reimbursement. The workshop will be beneficial for policymakers, pharmaceutical industry, academics, regulators, healthcare professionals and for the students of pharmacy, medicine, economics, public policy, public health, and law.